According to Zacks, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. “
A number of other equities analysts also recently weighed in on the stock. Stifel Nicolaus reaffirmed a buy rating and issued a $30.00 price target (down from $64.00) on shares of Esperion Therapeutics in a research note on Saturday. Chardan Capital reiterated a neutral rating and issued a $12.50 price objective on shares of Esperion Therapeutics in a report on Saturday. Credit Suisse Group AG upped their price objective on shares of Esperion Therapeutics from $10.00 to $14.00 and gave the stock an underperform rating in a report on Friday. Barclays PLC set a $13.00 price objective on shares of Esperion Therapeutics and gave the stock a hold rating in a report on Wednesday, August 31st. Finally, Vetr cut shares of Esperion Therapeutics from a strong-buy rating to a buy rating and set a $12.60 price objective for the company. in a report on Tuesday, August 23rd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company. Esperion Therapeutics currently has an average rating of Hold and an average target price of $26.36.
Shares of Esperion Therapeutics (NASDAQ:ESPR) traded up 0.858% during mid-day trading on Monday, reaching $12.345. The company had a trading volume of 16,237 shares. The company’s 50-day moving average price is $12.38 and its 200-day moving average price is $13.89. The company’s market capitalization is $278.38 million. Esperion Therapeutics has a 52-week low of $9.58 and a 52-week high of $30.41.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.16. During the same quarter last year, the company earned ($0.55) earnings per share. On average, analysts forecast that Esperion Therapeutics will post ($3.37) earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in ESPR. Quantitative Investment Management LLC bought a new position in shares of Esperion Therapeutics during the second quarter worth approximately $111,000. Advisor Group Inc. acquired a new position in Esperion Therapeutics during the second quarter valued at about $140,000. Stifel Financial Corp raised its position in Esperion Therapeutics by 10.6% in the second quarter. Stifel Financial Corp now owns 15,017 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 1,438 shares during the period. Rhumbline Advisers raised its position in Esperion Therapeutics by 27.0% in the second quarter. Rhumbline Advisers now owns 17,186 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 3,657 shares during the period. Finally, ProShare Advisors LLC raised its position in Esperion Therapeutics by 1.3% in the second quarter. ProShare Advisors LLC now owns 18,533 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 238 shares during the period. 65.23% of the stock is owned by institutional investors and hedge funds.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.